Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Current Treatments for Type 2 Diabetes
  • Metformin
  • Sulfonylureas
  • Peroxisome Proliferator-Activated Receptor-Gamma Agonists
  • Glucagon-Like Peptide-1 Analogues
• The Type 2 Diabetes Market
  • 2007 Sales and Prescriptions
  • Uptake of New Agents in the Type 2 Diabetes Market
    • PPAR-γ Agonists
    • Byetta
• Januvia-First in Class
  • Mechanism of Action
  • Clinical Trial Results
  • Januvia' s Uptake in the Market
• Emerging Competition
  • Novartis' s Galvus
  • Takeda' s Alogliptin
  • Bristol-Myers Squibb/AstraZeneca' s Saxagliptin
  • Early-Stage DPP-IV Inhibitors
• Outlook for DPP-IV Inhibitors

Tables:

• 1. Worldwide Sales of Agents Commonly Prescribed to Treat Type 2 Diabetes, 2007
• 2. Emerging Glucagon-Like Peptide 1 Analogues and Peroxisome Proliferator-Activated Receptor Agonists
• 3. Physiological Functions of the Incretins GLP-1 and GIP

Figures:

• 1. Typical Decision Tree for Type 2 Diabetes, 2008
• 2. Market Share of Drug Classes to Treat Type 2 Diabetes, 2007
• 3. Sales of Newly Launched Agents to Treat Type 2 Diabetes, 2000-2006
• 4. Volume Share of Drug Classes Used to Treat Type 2 Diabetes, First Half of 2007
• 5. U.S. Sales of Januvia by Quarter, 2006-2007